CEO and Founder Dr Sunghoon Kim—leading at the forefront of ARS science
Our studies in aminoacyl-tRNA synthetase (ARS) science are led by CEO and Founder Dr Sunghoon Kim, who has a profound passion for research in ARSs. Dr Kim has devoted more than 30 years to advancing this science to benefit the next generation of game-changing targets.
Dr Sunghoon Kim
Dr Kim is recognized as a pioneer who uncovered epi-translational activities of ARSs hidden underneath their catalytic roles. Dr Kim is a Horace G. Underwood distinguished professor at Yonsei University College of Pharmacy & Severance Hospital.
Dr Kim’s discoveries on the new physiological and pathological functions, and the potential therapeutic uses of ARSs are rapidly opening a research area that casts new insights into the central dogma of life and human diseases. He is the top ranked in the tRNA synthetase researcher in the field. In addition, the annual publication and citation numbers of research articles published by his group are persistently increasing.
Dr Kim has a PhD from Brown University and was a postdoctoral fellow at MIT. He was the first employee at Cubist Pharmaceuticals before returning to Korea to begin his career in academia. He won a series of prestigious prizes such as Ho-Am Prize for Medicine, the Scientist of the Year, and the National Best Scientist prize.
Meet our team
Nam Hoon Kwon
Founder, CTO Research and Development
|
With extensive expertise in ARS-based early drug discovery, Nam Hoon Kwon brings a wealth of knowledge and experience to ZYMEDI. With a PhD from Seoul University and a DVM in veterinary medicine, Dr Kwon has been Chief Development Officer at Medicinal Bioconvergence Research Center and CDO at Biocon, and CTO at Oncotag Diagnostics. Dr Kwon was a Research Professor at Seoul National University, and is the recipient of Man of Merit (R&D), awarded by the Ministry of Science, ICT and Future Planning, South Korea. |
Hyuk-Sang Kwon
Vice President, CDO Research and Development
Hyuk Sang Kwon brings extensive experience to ZYMEDI. Before joining ZYMEDI, Dr Kwon served as Group Managing Director, Head of Biological Research, and Biologics R&D Reader at Ildong Pharmaceuticals. Dr Kwon has a PhD from Seoul National University.
Hyeong Jin Kim
CFO
An expert in bio-health, Hyeong Jin Kim is a KICPA and holds a BS from Korea University. Kim has served as CSO at EONE Laboratories, was head of the Center for Future Innovation at Samsung Medical Center, and was a healthcare group partner at KPMG.
He serves on the Board of Directors of the Korean Society of Healthcare Design and Korean Society of Hospital Management and on the advisory board of the Korea Healthcare Congress.
Scott Kim
CBO, Business Development
An expert in BD LS strategy, he has served as Head of BD&S at Helixmith, Director of Strategic Advisory at Deloitte LSHC, CBO at RaND Biosciences, and Manager at SK Biopharmaceuticals. He graduated with a BA from the University of Minnesota, Twin Cities.
Choul Hong Park
Director, Medichem Department
A medicinal chemistry expert, Choul Hong Park has a PhD from Tohoku University and has done postdoctoral research at International School Tokyo and the University of Illinois.
Before joining the ZYMEDI leadership team, Dr Park was Managing Researcher at Legochem Bioscience, and Director at LG and Samsung. He has also worked at Crystal Genomics and LegoChem Biosciences.
Dr Park also serves on the advisory board at Deloitte.
Byung Ki Kim
COO
A human resources and administration expert, Byung Ki Kim earned an MBA in International Management at the Thunderbird Business School (Arizona State University).
He brings a wealth of experience to ZYMEDI, having worked in the Human Resources departments at MTV Networks Korea, LG Electronics, and Samsung. He has served as VP, Human Resources at Vivozon, and Director of Human Resources at Sun Food.
“Despite the great success of targeted therapy, there are still many patients who do not get therapeutic benefit from the existing drugs.”
